Skip to main content
14 search results for:

Darolutamide 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 14-02-2023 | Prostate cancer | News | Article

    Maintenance darolutamide shows promise in metastatic CRPC

    Phase 2 data point to the potential of switch maintenance with darolutamide in men with metastatic castration-resistant prostate cancer that has not progressed after taxane therapy.

  2. 30-01-2023 | EMA | News | Article
    approvalsWatch

    EMA recommends new indication for darolutamide

    medwireNews : The EMA has recommended that the indication for darolutamide be expanded to include the treatment of metastatic hormone-sensitive prostate cancer (HSPC).

  3. 15-08-2022 | FDA | News | Article
    approvalsWatch

    Darolutamide approved in USA for metastatic HSPC

    Darolutamide should be given  at a dose of 600 mg twice daily with food, with docetaxel 75 mg/m 2 administered every 3 weeks for up to six cycles.

  4. 18-02-2022 | ASCO GU 2022 | Conference coverage | Article

    Darolutamide add-on prolongs survival in mHSPC

    Adding the androgen receptor inhibitor darolutamide to androgen-deprivation therapy plus docetaxel significantly improves overall survival in men with metastatic hormone-sensitive prostate cancer, show data from the phase 3 ARASENS trial.

  5. 24-11-2020 | Castration-resistant prostate cancer | Adis Journal Club | Article
    Targeted Oncology

    Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer

    Albeit long-term data from the real-world setting are required to fully define the safety profile of darolutamide, current evidence from the final ARAMIS analysis indicates that darolutamide has a low propensity for CNS-related adverse events (AEs) associated with other currently approved second-generation AR inhibitors.

  6. 04-02-2020 | EMA | News | Article
    approvalsWatch

    Darolutamide receives positive EMA decision for nonmetastatic CRPC

    Darolutamide is the third antiandrogen, after enzalutamide  and apalutamide , to receive a positive opinion from the EMA for this indication.

  7. 02-08-2019 | FDA | News | Article
    approvalsWatch

    Darolutamide added to armamentarium for nonmetastatic CRPC

    medwireNews : Darolutamide is the latest nonsteroidal antiandrogen to receive a positive decision from the US FDA for the treatment of men with nonmetastatic castration-resistant prostate cancer (CRPC).

  8. 18-02-2019 | Castration-resistant prostate cancer | News | Article
    ASCO GU 2019

    Darolutamide reduces CRPC metastasis risk

    Addition of the androgen receptor antagonist darolutamide to androgen deprivation therapy improves metastasis-free survival in patients with castration-resistant prostate cancer, indicate ARAMIS trial results.

  9. 01-06-2019 | Castration-resistant prostate cancer | News | Article

    ARAMIS QoL results add support for darolutamide in nonmetastatic CRPC

    Men with nonmetastatic castration-resistant prostate cancer enrolled in the ARAMIS trial report favorable quality of life outcomes with darolutamide relative to placebo.

  10. 02-08-2021 | Prostate cancer | News | Article

    Second-generation androgen receptor inhibitors supported for older nonmetastatic CRPC patients

    The exploratory pooled analysis included the 4117 participants of the placebo-controlled PROSPER, SPARTAN, and ARAMIS trials that evaluated the second-generation ARIs enzalutamide, apalutamide, and darolutamide, respectively, in nonmetastatic CRPC patients with a prostate-specific antigen level of at least 2.0 µg/L and a doubling time of 10 months or less.

  11. 02-12-2020 | Prostate cancer | News | Article

    Androgen receptor inhibitors implicated in fall, fracture risk in prostate cancer

    The rates of all-grade falls and fractures differed by ARI type, with the highest incidence seen with apalutamide, at 12.0% and 10.0%, respectively, followed by enzalutamide (8.0 and 1.8%, respectively) and darolutamide (4.2 and 4.2%, respectively).

  12. play
    31-05-2020 | ASCO 2020 | Conference coverage | Video

    Expert comment: Antiandrogens in nonmetastatic CRPC

    Tomasz Beer highlights the key messages and caveats of the overall survival data from the PROSPER, SPARTAN, and ARAMIS trials of enzalutamide, apalutamide, and darolutamide, respectively, in the nonmetastatic castration-resistant prostate cancer setting (10:25).

  13. 24-06-2020 | ASCO 2020 | Conference coverage | Article

    Antiandrogen therapy boosts nonmetastatic CRPC survival

    Darolutamide was also associated with significant delays in the time to pain progression, first cytotoxic chemotherapy, and first symptomatic skeletal event.

  14. 08-04-2019 | Castration-resistant prostate cancer | News | Article

    SPARTAN: Apalutamide benefit seen for luminal, basal nonmetastatic CRPC

    . © 2019 Springer Healthcare part of the Springer Nature group AACR Annual Meeting 2019; Atlanta, Georgia, USA: 29 March–3 April See also: Androgen receptor inhibition delays CRPC metastasis SPARTAN: Adding apalutamide to ADT does not diminish nonmetastatic CRPC HRQoL FDA nod for apalutamide for nonmetastatic CRPC Enzalutamide receives FDA approval for nonmetastatic CRPC Darolutamide reduces CRPC metastasis risk

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.